Clinicopathological and histopathological findings. Age, sex, and
tumor size were evaluated. Clinical outcomes were evaluated based
on the history of local recurrence, distant metastasis, and death as
a result of the tumor. Histopathological progression of each
carcinoma was also evaluated using TNM classification.

Immunohistochemistry. Immunohistochemical staining was performed
for all 11 cases. Formalin-fixed, paraffin-embedded tissue was
sectioned (3 μm). The primary antibodies used, their dilutions, and
antigen retrieval are summarized in Table I. The immune complexes
were detected using the DAKO EnVision Detection System (Santa
Clara, CA, USA). Immunohistochemical staining of >10% of
carcinoma cells was considered a positive result.

Results

Clinicopathological and histopathological findings. Survival
data were available for all 11 patients (100%), with follow-
up ranging from 6 to 136 months (mean=31.6 months,
median=20 months). Clinicopathological findings are
summarized in Table II. The age of the patients ranged from
48 to 85 years (mean=71.5 years, median=74 years) and the
male:female ratio was 5:6. The area of the invasive
carcinoma ranged in size from 0.2 to 8.5 cm in diameter
(mean=3.9 cm, median=4.0 cm) and the size of the pagetoid
spread ranged from 0.2 to 17.5 cm in diameter (mean=6.5
cm, median=8.0 cm). Local recurrence occurred in one
(9.1%) case, distant metastasis occurred in five (45%) cases,
and four (36%) patients died from their disease.

Grossly, areas of invasive carcinoma were evident in nine
cases but were lacking in the remaining two. Representative
histological findings are shown in Figure 1. Histopathologically,
all tumors contained areas of pagetoid spread, and nine tumors
had invasive carcinomatous components. The TMN
classification for each tumor is summarized in Table II. Of the
nine tumors with invasive carcinomatous components, tubular
adenocarcinoma was present in eight and neuroendocrine
carcinoma (NEC) without tubular adenocarcinoma was present.

Table I. Immunohistochemical antibodies used in this study.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Source</th>
<th>Clone</th>
<th>Species</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytokeratin 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytokeratin 20</td>
<td></td>
<td>Ks 20.8</td>
<td>Mouse</td>
<td>1:50</td>
</tr>
<tr>
<td>Estrogen receptor</td>
<td>DAKO, Santa Clara, CA, USA</td>
<td>EP1</td>
<td>Rabbit</td>
<td>1:1</td>
</tr>
<tr>
<td>Progesterone receptor</td>
<td>DAKO, Santa Clara, CA, USA</td>
<td>PgR 636</td>
<td>Mouse</td>
<td>1:1</td>
</tr>
<tr>
<td>Human epidermal growth factor</td>
<td>Polyclonal</td>
<td></td>
<td>Rabbit</td>
<td>1:250</td>
</tr>
<tr>
<td>p63</td>
<td>DAKO, Santa Clara, CA, USA</td>
<td>DAK-p63</td>
<td>Mouse</td>
<td>1:1</td>
</tr>
<tr>
<td>Caudal type homeobox 2</td>
<td>BioGenex, Fremont, CA, USA</td>
<td>CDX2-88</td>
<td>Mouse</td>
<td>1:100</td>
</tr>
<tr>
<td>GATA-binding protein 3</td>
<td>CELL MARQUE, Rocklin, CA, USA</td>
<td>L50-823</td>
<td>Mouse</td>
<td>1:100</td>
</tr>
<tr>
<td>Gross cystic disease fluid-protein-15</td>
<td>Leica, Wetzlar, Germany</td>
<td>23A3</td>
<td>Mouse</td>
<td>1:20</td>
</tr>
</tbody>
</table>